Granata Bio – a biopharma company focused on invigorating the global infertility medication market – announced its $15 million Series A+ funding round. The funding round was exclusively supported by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, and other strategic investors. And Granata has raised over $30 million to date.
This funding round will primarily support Granata Bio’s efforts to progress its existing pipeline and explore new innovative assets in reproductive health. With this funding round, Granata Bio is focused on strengthening its leadership within the reproductive health space and continuing to identify and grow innovative solutions for patients.
Granata Bio was represented by Mintz for the funding round.
KEY QUOTE:
“We are grateful for the continued confidence and commitment shown by our existing investors, especially our strategic partners who are leaders in women’s health, Gedeon Richter and CooperSurgical. Granata Bio is committed to improving access for fertility patients by identifying and developing new therapeutic solutions. With this new funding, we are well-positioned to accelerate the development of our current and future pipeline.”
- Evan Sussman, CEO of Granata Bio
